LabyRx is a clinical-stage immuno-oncology company focused on developing the next-generation of novel therapeutic vaccines and antibody therapies to improve the lives of cancer patients worldwide.

Our lead product, LabVax, is a Labyrinthin-derived peptide vaccine that recruits the body’s immune cells to attack adenocarcinoma tumors. It expands on the successful first-into-human clinical trial at the Chinese University of Hong Kong that used a vaccine prototype to the current LabVax.

LabVax has been approved by the US FDA for human clinical trials that are now being conducted in concert with the University of California, Davis and National Cancer Institute.